Highlights
Launched the Pfizer Medicine Safety Education Web site (www.pfizer.com/medicinesafety), which works to bridge the gap in knowledge about how medicine safety is determined, monitored, and communicated to health care professionals, patients and journalists.
Continued to rigorously conduct reviews of all existing nonclinical safety data prior to testing a drug candidate for the first time in a human clinical trial.
Provided anti-counterfeiting training to enforcement agencies and continue to test products free of charge to determine their authenticity. Since the program's inception in 1998, training for authorities has been conducted in 79 countries.
Patient safety is a paramount concern for Pfizer from the moment a new compound is discovered, and for as long as a medicine is prescribed. It is our ethical and regulatory responsibility to monitor the safety of our medicines everywhere they are marketed. Once a drug compound is approved, we continue to monitor its safety and work with governments and others to secure the supply chain and prevent counterfeiting.
We are committed to broadening safety awareness and therefore strive to improve patient safety communications. We are also exploring mechanisms to improve communications between Pfizer and patients and health care professionals, when adverse effects are reported, so that we can aggregate data and respond appropriately. Pfizer employs more than 2,000 medicine safety specialists including research scientists, physicians, nurses, pharmacists, epidemiologists and others. These colleagues work with regulatory authorities to understand, as precisely as possible, the risks and benefits of our medicines before and after they are cleared by regulatory authorities. Our safety processes include collecting adverse event reports, conducting observational studies, and funding independent safety studies that are conducted by third-party investigators.
Read more about Patient Safety in PDF